Page 6 - Serum Institute Of India

Will vaccine crunch hurt India's ongoing fight against Covid-19?

Serum Institute is going to cut down production of Covishield as there's no order from the govt. But some states don't have enough vaccine in store. Find out if India is well-stocked to fight Covid-19

Serum may cut Covishield's monthly production by half as govt orders dry up

The Pune-based firm has 500 million doses of Covishield in stock

SII may cut Covishield's monthly production by half amid demand slump

SII has written to the government to seek clarity on its requirement for normal two doses and also on booster doses

SII seeks DCGI's approval for Covishield as booster dose: Report

In an application to DCGI, an SII official cited that the UK's Medicines and Healthcare products Regulatory Agency has already approved the booster dose of AstraZeneca's vaccine, say sources

SII resumes exports to COVAX, produces 1.25 bn Covishield doses this year

The first batches of Covishield left the SII manufacturing facility in Pune earlier today, for distribution to low- and middle-income countries

Serum Institute resumes Covishield exports under COVAX facility

SII said its supply of doses via COVAX was expected to increase substantially into the first quarter of 2022

Covid-19 jab exports set to rise; Serum Institute leads the pack

Indonesia to get 5 mn Covovax doses, exports to COVAX to rise to 30 mn by Jan

Serum Institute urges govt to speed up movement of rising Covishield stock

Serum Institute of India has urged the government to fast-track Covishield movement citing the difficulties being faced in production and cold chain space planning for other vaccines

Vaccine hesitancy greatest threat in overcoming Covid: Adar Poonawalla

Serum Institute of India CEO Adar Poonawalla on Wednesday termed vaccine hesitancy as the greatest threat in overcoming the COVID-19 pandemic while urging all adults to get vaccinated at the earliest

Govt allows SII to export 5 cr doses of Covid vaccine Covovax to Indonesia

The government has permitted export of 5 crore doses of Covovax, a Covid-19 vaccine domestically produced here by the Serum Institute of India

SC to hear plea seeking disclosure of data on Covid shots' trials on Nov 29

The apex court had earlier in August asked the Centre, Bharat Biotech, SII, and others to respond to the plea which sought directions to also disclose post-vaccination data regarding adverse events

Novavax files for emergency use listing of Covid-19 vaccine with WHO

Biotechnology firm Novavax Inc said it has completed the rolling submission for the emergency use listing (EUL) of its COVID-19 vaccine candidate to the World Health Organization (WHO). Earlier on Monday, Novavax and its partner Serum Institute of India (SII) had said that they had received the first emergency use authorisation (EUA) for COVID-19 vaccine in Indonesia. "The company has now completed the submission to World Health Organization (WHO) of all modules required for the regulatory evaluation of NVX-CoV2373, the company's recombinant nanoparticle protein-based COVID-19 vaccine with Matrix-M adjuvant," Novavax Inc said in a statement on Thursday. The chemistry, manufacturing and controls module submitted to WHO, as well as other regulatory agencies worldwide, leverages Novavax' manufacturing partnership with the SII, the world's largest vaccine manufacturer by volume, it added. Novavax will make further submissions to enable vaccine supply from additional manufacturing sites

Novavax, SII get emergency use authorisation for Covid vaccine in Indonesia

The vaccine will be manufactured by SII in India and marketed by it in Indonesia under the brand name Covovax, Novavax Inc said in a statement

SII seeks regular marketing authorisation from DCGI for Covishield

If the DCGI grants regular marketing authorisation, Covishied will be the second vaccine in the world to receive such approval

Vaccine working on new variants next challenge: SII CEO Adar Poonawalla

'We are delivering 220 million doses a month, and almost everything is being consumed', said Poonawalla

Australia drugs regulator approves Covishield for incoming travelers

It is not immediately clear whether the TGA's approval for Covishield will facilitate immediate travel to Australia by Indian students waiting to return to that country

Australia drugs regulator approves India-made AstraZeneca vaccine for Covid

China-made vaccine recognised as well as Australia starts to unwind some of the world's most intense pandemic border restrictions.

Serum Institute gets nod to start Covovax trials on children above 7 yrs

Co has already started trials on 12-year-olds and above; trials will start phase wise in children; Poonawalla has said by Jan-Feb trial data may be ready to seek approval

Top headlines: Sebi clears gold exchange framework; NCLT relief for Future

Business Standard brings you the top headlines on Tuesday

DCGI allows Serum to enrol 7-11 year olds in Covid vaccine trial

So far, only drugmaker Zydus Cadila's DNA Covid vaccine has received emergency use approval in India to be used in adults and children aged 12 years and above